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ABSTRACT
Background. Long-term shoulder and arm function fol-
lowing sentinel lymph node biopsy (SLNB) may surpass
that following complete axillary lymph node dissection
(CLND) or axillary lymph node dissection (ALND). We
objectively examined the morbidity and compared out-
comes after SLNB, SLNB ? CLND, and ALND in stage I/
II breast cancer patients.
Materials and Methods. Breast cancer patients who had
SLNB (n = 51), SLNB ? CLND (n = 55), and ALND
(n = 65) were physically examined 1 day before surgery
(T0), and after 6 (T1), 26 (T2), 52 (T3), and 104 (T4)
weeks. Differences in 8 parameters between the affected
and unaffected arms were calculated. General linear mod-
els were computed to examine time, group, and interaction
effects.
Results. All outcomes changed signiﬁcantly, mostly non-
linearly, over time (T0–T4). Between T1 and T4,
limitations decreased in abduction (all groups); anteﬂexion,
abduction-exorotation, abduction strength (SLNB ? CLND,
ALND); ﬂexion strength (SLNB ? CLND); and arm vol-
ume (SLNB, SLNB ? CLND). At T4, limitations in
anteﬂexion (SLNB, ALND), abduction (SLNB ? CLND,
ALND), exorotation (ALND), abduction-exorotation (all
groups), and volume (SLNB ? CLND, ALND) increased
signiﬁcantly compared with T0. The SLNB group showed
an advantage in anteﬂexion, abduction, abduction-exoro-
tation, and volume. Groups changed signiﬁcantly but
differently over time in anteﬂexion, abduction, abduction/
exorotation, abduction strength, ﬂexion strength, and vol-
ume. Effect sizes varied from 0.19 to 0.00.
Conclusion. Initial declines in range of motion and
strength were followed by recovery, although not always to
presurgery levels. Range of motion and volume outcomes
were better for SLNB than ALND, but not strength. SLNB
surpassed SLNB ? CLND in 2 of the range of motion
variables. The clinical relevance of these results is
negligible.
Breast cancer is the most common form of cancer in
women in the Western world. At some time during their
life, breast cancer will be diagnosed in about 1 of every 8
women.
1 Over the past few years, the 5-year survival rate
has increased by about 10% with the introduction of breast
cancer screening and improved adjuvant chemotherapy
 The Author(s) 2010. This article is published with open access
at Springerlink.com
First Received: 23 June 2009;
Published Online: 11 March 2010
H. J. Hoekstra, MD, PhD
e-mail: h.j.hoekstra@chir.umcg.nl
Ann Surg Oncol (2010) 17:2384–2394
DOI 10.1245/s10434-010-0981-8and/or hormonal therapy.
2 At present, the 5-year survival
rate is almost 90%.
1 Changes in the ﬁeld of surgical
treatment over the past 20 years have involved a decrease
in the extent of breast surgery (surgery according to Hal-
stedt, Patey, Madden, and breast-conserving therapy
[BCT]) and the introduction of minimally invasive staging
of the axilla by means of sentinel lymph node biopsy
(SLNB). In women with stage I–II breast cancer whose
clinical or ultrasound axillary ﬁndings are not suspicious,
the introduction of SLNB has meant that, at present, an
axillary lymph node dissection (ALND) can be omitted in
two-thirds to three-quarters of women.
3–5
Since the introduction of SLNB in the treatment of breast
cancer more than 15 years ago, there have been more than
1600 publications on the clinical application of SLNB in
breast cancer (PubMed keywords: sentinel node, breast,
study). These studies showed that, despite the less-invasive
nature of SLNB, there is still a risk of treatment-related
morbidity, such as paraesthesia, limitations in movement of
the shoulder and arm, or lymphedema of the arm.
5,6
A total of 20 studies made objective evaluations of the
function of the shoulder/arm and lymphedema of the arm in
women with stage I–II breast cancer and compared patients
after SLNB with patients after ALND.
4,6–24 The results of
these studies were inconsistent. For example, 12 studies
showed fewer functional complaints in the shoulder and
arm after SLNB than after ALND.
6,9–15,17,18,20,21 In con-
trast, the 8 remaining studies showed similar morbidity
complaints after SLNB or ALND.
4,7,8,16,22–24 The majority
of these studies were retrospective and focused on range of
motion limitations and the prevalence of lymphedema in
the arm. Only 2 retrospective studies and 1 prospective
study described objective measurements of muscle strength
in the arm.
6,9,18 Lastly, only 4 studies assessed shoulder/
arm morbidity preoperatively and at multiple time points
postoperatively. Three of these studies found less lymph-
edema after SLNB than after ALND, whereas the fourth
study found no difference in lymphedema.
8,10,15,20 The 2
studies that evaluated range of motion found fewer limi-
tations in 1 functional shoulder measurement after SLNB
than after ALND.
10,15
To gain more insight into the longitudinal course of the
function of the shoulder/arm, and the level of lymphedema
in the arm in patients with stage I–II breast cancer who had
undergone SLNB or SLNB and complete axillary lymph
node dissection (CLND), or ALND, we performed a lon-
gitudinal study. We expected (1) no preoperative
complaints about the range of motion of the shoulder, arm
strength, and volume of the arm (lymphedema) on the
affected side in any of the women in any of the groups, but
expected the presence of these complaints postoperatively;
(2) decreases in shoulder/arm complaints in women in the 3
groups over time; and (3) fewer functional shoulder/arm
complaints after SLNB than after SLNB ? CLND, or
ALND.
This study formed part of a large longitudinal prospec-
tive study on functional complaints and quality of life after
surgical treatment for breast cancer.
6,25
METHODS
Patients
Over a 2-year period, all patients with stage I and II
breast cancer at the University Medical Centre Groningen
and the Martini Hospital Groningen were informed about
this study by the nurse practitioner and invited to partici-
pate. Patients with preexisting shoulder complaints who
had been treated in the past with surgery, conservative
treatment, medication, and/or physiotherapy, and patients
with distant metastases were excluded. The study was
approved by the Medical Ethics Committees of the 2
hospitals. Participants agreed to take part by signing an
informed consent form.
On the day before surgery (T0), the ﬁrst measurements
were taken by a physician or physiotherapist. The mea-
surements were repeated 6 weeks (T1, median =
1.44 months), 6 months (T2, median = 5.92 months),
12 months (T3, median = 11.99 months), and 24 months
(T4, median = 23.95 months) postoperatively.
Treatment
The surgical SLNB technique was described by us
previously.
26 At the 2 hospitals, breast cancer was treated
according to the protocol described in the Dutch guidelines
for breast cancer.
27 When metastases were detected in the
sentinel lymph node, level I–II CLND was performed
within 2 weeks. All patients who received BCT underwent
adjuvant radiotherapy to the breast. When indicated,
patients received adjuvant systemic and/or hormonal
treatment with or without adjuvant locoregional radio-
therapy. Postoperatively, all women received written
instructions on standardized exercises of the upper
extremities to optimize mobility and function of the
affected arm. A physiotherapist instructed all patients on
how to perform these exercises in a 20-minute session.
Physical Examination
Range of motion including anteﬂexion, abduction,
exorotation, and combination abduction-exorotation were
measured in degrees according to a standardized protocol
using a goniometer (Isomed inclinometer, Portland, OR).
28
Muscle strength in the arm abductors and elbow ﬂexors
was measured in Newtons using a handheld dynamometer
A Longitudinal Comparison of Arm Morbidity 2385(Citec, Groningen, The Netherlands).
29 Grip strength was
measured in kilograms using a Jamar handheld dyna-
mometer (Sammons Preston Patterson Medical Division,
Bolingbrook, IL).
30,31
Arm measurements were taken at 4-cm intervals using a
tape measure, and the volume was calculated in milliliters
according to the method described by Sitzia.
32
Difference scores were used to express functional limi-
tations; the results on the affected side were subtracted
from the results on the nonaffected side. The larger the
difference in range of motion or strength scores between
the left and right shoulder or arm, the greater the functional
limitations. The larger the difference in volume between
the 2 arms, the more severe the lymphedema in the affected
arm. Difference scores were used in the statistical analyses.
Statistical Analyses
Descriptive statistics (chi-square and t tests) were used
to evaluate the data and to test for differences between
groups. The general linear model (GLM) procedure was
used to calculate longitudinal time, treatment, and inter-
action (time 9 treatment) effects based on the difference
scores from the shoulder and arm measurements and arm
volume. Posthoc Bonferroni tests were used when the
GLM procedure detected group effects. To test whether
shoulder/arm function had recovered to the original level
2 years after surgery, the results obtained at T0 (preoper-
ative values) and T4 (2 years after surgery) were compared
using paired t tests. To map longitudinal recovery after
surgical intervention, paired t tests were also used to
compare T1–T4. Effect sizes were calculated to determine
the level of clinical relevance of an effect: an effect size
between 0.20 and 0.49 reﬂected a small clinically relevant
difference; an effect size between 0.50 and 0.80 indicated a
moderate clinically relevant difference, and an effect
size[0.80 indicated a large clinically relevant differ-
ence.
33 P values\.05 were considered signiﬁcant. All
statistical analyses were carried out with SPSS 14 (Statis-
tical Package for Social Sciences, SPSS Inc., Chicago, IL).
RESULTS
A total of 209 patients were informed about the study
before their operation, and invited to participate; of these, 6
patients refused. Postoperatively, 8 patients were found to
be not eligible for the study: 3 patients had benign tumors, 2
patients had ductal carcinoma in situ (DCIS), 2 patients had
a T4 tumor, and the primary tumor could not be found in 1
patient. Therefore, 195 of the 201 eligible patients partici-
pated in this study (97%). Of these, 61 received SLNB, 59
received SLNB ? CLND, and 75 received ALND. T1
measurements were taken from 185 (95%), T2 measure-
ments from 183 (94%), T3 measurements from 178 (91%),
and T4 measurements from 171 (88%) patients. The reasons
24 patients provided for dropping out during the study
period (10 SLNB, 4 who received SLNB ? CLND, and 10
who received ALND) were the following: 7 patients died
from the disease, 2 patients developed metastases, 1 patient
was excluded due to breast reconstructive surgery, 7
patients stopped because of lack of interest, and 7 patients
missed 1 of the measurements (Fig. 1).
The median age of the 171 participants was 54 (range
31–84) years. There were no signiﬁcant differences in age
or body mass index between the 3 groups. As expected,
TNM classiﬁcation, surgical treatment (lumpectomy, radi-
cal mastectomy), number of dissected lymph nodes,
complications, radiotherapy, and systemic therapy differed
signiﬁcantly between the groups (Table 1). At T0, the 3
groups had comparable difference scores between the
affected and nonaffected sides on range of motion, muscle
strength, and arm volume (data not shown).
The GLM procedure was performed with the variables
in which the three study groups differed, with the exception
of tumor stage because this variable was a determinant
factor for further adjuvant treatment. This was done to
examine the effect of these variables on shoulder and arm
functioning and whether including these variables as a
between-subjects factor would produce different results
from the procedures including groups according to SLNB,
SLNB ? CLND, or ALND.
Range of Motion
Signiﬁcant time effects were found in the difference
scores for the 4 functional shoulder measurements (Fig. 2).
These changes-over-time were not linear for abduction,
anteﬂexion, and abduction-exorotation. An increase in the
limitations in these functions in the affected shoulder at
T0–T1 was followed by a decrease in limitations between
T1 and T4 (Fig. 2). The decrease in limitations in abduc-
tion in the affected shoulder between T1 and T4 was
signiﬁcant in all 3 groups, while the decreases in limita-
tions in anteﬂexion and abduction-exorotation were
signiﬁcant in the SNLB ? CLND and ALND groups.
Compared with T0, at T4, the decrease in limitations in
anteﬂexion in the affected shoulder at T4 was signiﬁcant in
the SLNB and ALND groups, decrease in limitations in
abduction was signiﬁcant in the SLNB ? CLND and
ALND groups, and decrease in limitations in abduction-
exorotation was signiﬁcant in all 3 groups. Changes over
time in the affected shoulder showed a linear course for
exorotation. At T4, the limitations in exorotation in the
affected shoulder were signiﬁcantly larger than at T0 in the
ALND group, but not in the other two groups (Table 2).
2386 J. J. Kootstra et al.Signiﬁcant group effects were found in the difference
scores for anteﬂexion, abduction, and abduction-exorota-
tion, but not for exorotation (Fig. 2). These showed an
advantage in the SLNB group compared with the
SLNB ? CLND and ALND groups for anteﬂexion and
abduction, as well as compared with the ALND group for
abduction-exorotation (Fig. 2).
Interaction effects (time 9 group) were signiﬁcant for
the difference scores in anteﬂexion, abduction, and
abduction-exorotation (Fig. 2). Whereas the limitations in
the affected shoulder in the SLNB group remained com-
parable after T1 or T2, limitations in the ALND and
SLNB ? CLND groups decreased after T1 (Fig. 2). Effect
sizes varied between 0.01 and 0.19 (Fig. 2).
Muscle Strength
Signiﬁcant time effects were found in the difference
scores from the three functional arm measurements
(Fig. 3). The course was not linear. Increases in limita-
tions in the affected arm between T0 and T1 were
followed by decreases between T1 and T4 (Fig. 3). These
decreases between T1 and T4 were signiﬁcant for
abduction strength in the SLNB ? CLND and ALND
groups, and for ﬂexion strength in the SLNB ? CLND
group. Changes in limitations in the affected arm in grip
strength between T1 and T4 were not signiﬁcant in any of
the groups. No signiﬁcant differences in arm function
between T0 and T4 were found (Table 2). No signiﬁcant
group effects were found (Fig. 3).
Interaction effects were signiﬁcant for abduction
strength and ﬂexion strength (Fig. 3). Whereas limitations
in the affected arm in abduction and ﬂexion strength
remained constant in the SLNB group after T1, limitations
in abduction strength decreased in the ALND and
SLNB ? CLND groups, while limitations in ﬂexion
strength decreased in the SLNB ? CLND group (Table 2).
Effect sizes varied between 0.00 and 0.05 (Fig. 3).
209 contacted
203 surgery
195 participants
61 SLNB T0 59 SLNB+CLND 75 ALND
51 SLNB T4 55 SLNB+CLND 65 ALND
1
Died
3 3
1
Metastasis
1 0
0
Reconstruction
0 1
4
An assessment missing
0 3
4
Stopped
0 3
6 declined participation
8 Excluded
3 benign
2 DCISa
2 T4 breast cancer
1 OBCb
FIG. 1 Flowchart of patients. a Ductal
carcinoma in situ. b Occult breast cancer (no
primary tumor was found)
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Signiﬁcant time effects, group effects, and interaction
effects were found in the arm volume difference scores
(Fig. 3). Increases in arm volume were linear in the
ALND group, but not in the SLNB or SLNB ? CLND
groups. At T4, there was a signiﬁcant increase in arm
volume compared with T0 in the SLNB ? CLND and
ALND groups, but not in the SLNB group (Table 2,
Fig. 3).
Bonferroni tests showed that the increase in volume was
signiﬁcantly smaller in the SLNB group than in the ALND
group, but not signiﬁcantly smaller than in the
SLNB ? CLND group. The difference between the
SLNB ? CLND group and the ALND group was not sig-
niﬁcant. Effect sizes varied between 0.07 and 0.10 (Fig. 3).
TABLE 1 Patient descriptors and comparisons between groups
Variable SLNB (N = 51) SLNB ? CLND (N = 56) ALND (N = 65) Test value P
N (%) N (%) N (%)
Age, mean (SD) 57.9 (11.9) 53.8 (9.8) 56.9 (11.6) F = 2.30
b .104
TNM classiﬁcation X
2 = 45.11 \.001*
Stage I 38 (74.5) 8 (14.5) 27 (41.5)
Stage II A 12 (23.5) 41 (74.5) 26 (40.0)
Stage II B 1 (2.0) 6 (10.9) 12 (18.5)
Surgery X
2 = 16.30 \.001
BCT 35 (68.6) 39 (70.9) 25 (38.5)
Mastectomy 16 (31.4) 16 (29.1) 40 (61.5)
Dissected lymph nodes X
2 = 158.4 \.001
\3 removed 48 0 0
3–10 removed 1 20 25
[10 removed 0 32 37
Missing 2 4 3
Complications X
2 = 8.74 .013**
No 46 (89.7) 38 (61.5) 56 (65.9)
Yes
[4 weeks seroma 2 (4.2) 6 (14.0) 11 (19.3)
Inﬂammation
a 3 (6.1) 12 (24.5) 8 (14.8)
Radiotherapy X
2 = 11.47 .003***
No 16 (31.4) 12 (21.8) 33 (50.8)
Yes
Breast 35 (68.6) 39 (70.9) 25 (38.5)
Breast and axilla 0 (0.0) 4 (7.3) 7 (10.8)
Systemic therapy X
2 = 36.40 \.001****
No 37 (72.5) 8 (14.5) 28 (43.1)
Yes
Chemo ? hormonal - 4 (7.8) 8 (14.5) 13 (20.0)
Chemo ? hormonal ? 5 (9.8) 20 (36.4) 8 (12.3)
Chemo - hormonal ? 5 (9.8) 19 (34.5) 16 (24.6)
Body mass index, mean (SD) 25.4 (4.4) 25.0 (3.7) 26.1 (4.7) F = 0.26 .775
TNM tumor node metastasis, BCT breast-conserving treatment
a Inﬂammation treated with antibiotics
b One-way ANOVA
* Patients diagnosed with breast cancer stage I versus IIa and IIb
** No complications versus complications
*** No radiotherapy versus radiotherapy
**** No systemic treatment versus systemic treatment
2388 J. J. Kootstra et al.Effect of Treatment-Related Variables
Type of surgery and complications did not have any
signiﬁcant effect on the difference scores for range of
motion, strength, or arm volume. Chemotherapy signiﬁ-
cantly affected volume only. The consequential Bonferroni
tests showed that increases in arm volume were greater in
patients who received chemotherapy than in patients who
did not receive chemotherapy. Radiation signiﬁcantly
affected anteﬂexion and abduction. Patients who under-
went radiotherapy to the breast and axilla had more
limitations in anteﬂexion and abduction than patients who
did not undergo radiotherapy or who received radiotherapy
to the breast only. The number of dissected lymph nodes
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exorotation, and volume. Patients from whom 3–10 or
more than 10 lymph nodes were removed had more limi-
tations in their range of motion than patients who had fewer
than 3 nodes removed. Patients who had more than 10
lymph nodes removed had increased arm volume compared
with patients who had fewer than 3 or 3–10 nodes removed
(Table 3).
DISCUSSION
In this prospective study in patients with stage I–II
breast cancer, validated measurement methods were used
to evaluate the function of the shoulder, muscle strength,
and volume of the arm over a period of 2 years. It was
expected that the limitations in shoulder/arm function
would be largest in the immediate postoperative period,
TABLE 2 Descriptors of the differences between arms in range of motion, strength, and arm volume, and paired t tests
Variable T0 T1 T2 T3 T4 T0–T4 T1–T4
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) PP
Range of motion
D ant
SLNB 0.2 (4.1) 6.5 (10.6) 3.7 (6.1) 4.5 (9.1) 3.4 (7.8) .008 0.079
SLNB ? CLND 1.6 (10) 16.6 (17) 9.7 (12.9) 8.4 (14) 4.6 (9.4) .053 \.001
ALND 0.6 (5.5) 16.4 (16.1) 13.4 (19) 9.6 (12.4) 7.5 (12.8) \.001 \.001
D abd
SLNB 1.7 (12.9) 14.7 (24.2) 6.7 (14.7) 8.4 (14.6) 5.7 (15.2) .194 .007
SLNB ? CLND 1.4 (12.3) 34.7 (33.7) 20.3 (26.7) 17.1 (28.4) 12.2 (30) .017 \.001
ALND 0.4 (8.8) 31 (29.2) 23 (33.5) 20.8 (25.6) 18 (29.5) \.001 .008
D exo
SLNB 1.4 (6.7) -0.5 (8.3) 1.2 (10.2) 1.2 (8.6) 1.8 (9.6) .757 .082
SLNB ? CLND -0.4 (7.6) 1.7 (8.1) 0.9 (8.2) 1.5 (9.1) 1.8 (8.4) .113 .816
ALND -0.7 (7.9) 2.5 (9.7) 4.4 (15.6) 3.6 (10.6) 2.8 (8.7) .007 .837
Dabdexo
SLNB -0.2 (3.1) 4.8 (11.5) 2.5 (5.1) 3.9 (6.7) 3.1 (6.1) .001 .206
SLNB ? CLND 0.38 (3.4) 9.1 (12.8) 8.1 (11.6) 7.7 (13.3) 4.1 (11.3) .016 .011
ALND -0.1 (3.3) 12.4 (16.1) 9.9 (14.8) 9.4 (16.7) 6.7 (14.3) \.001 .004
Strength
D abds
SLNB 1.5 (23.6) 1.2 (20.8) -2.2 (26.6) -7.4 (25.1) 3.8 (25.6) .454 .425
SLNB ? CLND -3.4 (26.5) 14.2 (34.9) 4.9 (27.7) -2.6 (31.8) -2.2 (36.5) .813 .016
ALND -5 (25.7) 17.8 (26.8) 6.7 (28.6) 6.3 (32.4) 0 (30.9) .266 \.001
D ﬂexs
SLNB 2.7 (23.1) 0.4 (30.7) 5.9 (26) 4.1 (21.7) -3.1 (25.6) .223 .653
SLNB?CLND -2.2 (36.7) 16.9 (38.4) 3.5 (23.3) 4 (28.7) -0.8 (25.8) .928 .009
ALND -3.3 (24.2) 11 (30.1) 3.5 (31.4) 0.6 (30.7) 4 (27.8) .100 .081
D grips
SLNB 0 (4.8) 1 (5) 0 (4.7) -0.3 (4.8) 0.5 (3.8) .451 .365
SLNB?CLND 0.7 (4.5) 1.5 (3.7) 1.2 (4.5) 1.5 (4.5) 0.4 (4.2) .656 .055
ALND -0.3 (4.4) 1.9 (4.9) 1.4 (5.1) 1 (5.5) 0.8 (4.8) .115 .059
Arm volume
D vol
SLNB 14.2 (99.5) 0.8 (75.4) 4.1 (76.2) -0.1 (96.3) 24 (77.2) .349 .015
SLNB ? CLND -2.3 (103.8) -43.2 (97.6) -46.9 (122.1) -49.5 (137.7) -33.5 (148) .041 .512
ALND -4.1 (105.7) -57.3 (134) -76 (160.8) -94.1 (189.4) -116 (212) \.001 .010
D unaffected side - affected side, ant anteﬂexion, abd abduction, exo exorotation, abdexo combined movement of abduction and exorotation,
abds abduction strength, ﬂexs ﬂexion strength, grips grip strength, vol arm volume
2390 J. J. Kootstra et al.followed by improvement over the course of time, and that
the patients in the SLNB group would have less shoulder/
arm morbidity than those in the SLNB ? CLND and
ALND groups.
Range of Motion
Our hypothesis that reduced postoperative shoulder
function would be followed by improvement over the
subsequent 24 months was conﬁrmed in this study.
Recovery of shoulder function was also observed in
another study with a shorter follow-up of 12 months.
15
However, the initial postoperative deterioration in women
who underwent ALND was greater than that in the women
in the SLNB group. At the 2-year follow-up, women who
underwent SLNB still had limitations in 2 of the 4 shoulder
functions (anteﬂexion and abduction-exorotation) com-
pared with the preoperative measurements, whereas
women in the ALND group still had limitations in all 4
shoulder functions. Over the 24-month study period,
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A Longitudinal Comparison of Arm Morbidity 2391women in the SLNB group had fewer limitations in ante-
ﬂexion, abduction, and abduction-exorotation of the
shoulder than women in the SLNB ? CLND and ALND
groups. This result was in disagreement with 2 other
studies that reported initial differences in shoulder function
between the treatment groups that were no longer found at
the 3-month follow-up.
4,15 One explanation is that, in these
studies, the SLNB group also contained women in whom
SLNB had been followed by CLND or radiotherapy to the
axilla, owing to inclusion based on the intention to treat
principle. Three studies similar to ours and one retrospec-
tive study found an advantage in women who underwent
SLNB alone, which is in agreement with our
results.
6,10,11,13
Muscle Strength
This study showed signiﬁcant changes in muscle
strength over time. The patterns differed between the
SLNB, SLNB ? CLND, and ALND groups. In the axillary
lymph node dissection groups (SLNB ? CLND and
ALND), the postoperative reduction in abduction and
ﬂexion strength was larger than that in the SLNB group.
All the women (ALND, SLNB ? CLND, and SLNB
groups) recovered to their preoperative level at the 2-year
follow-up. This is in contrast to a 1-year follow-up study
that described an advantage of SLNB over ALND.
6
However, our results also contradict those of 2 retrospec-
tive studies that reported an advantage of SLNB over
ALND. One of the studies compared women who had
undergone SLNB 31 months previously to women who had
undergone SLNB ? CLND 56 months previously, a dif-
ference of 2 years.
18 In the second study, the results were
based on a summation score obtained using a questionnaire
that not only measured the subjective experience of muscle
strength, but also functional limitations, pain, dysesthesias,
and loss of sensitivity.
9
Arm Volume
This study conﬁrmed the expectation that arm volume
increased less after SLNB than after ALND. It was striking
that the volume of the affected arm continued to increase in
the ALND group over the course of 2 years, whereas in
women who underwent SLNB ? CLND, the initial
increase was followed by stabilization and, in the SLNB
group, there was no change compared with the preoperative
arm volume. Over the course of time, arm volume in the
ALND group differed signiﬁcantly from that of the SLNB
group, but there was no difference between the SLNB and
SLNB ? CLND groups. A difference between the SLNB
and ALND groups was also found after 1 year in another
study.
6 However, in that study, the last group included
ALND and SLNB ? CLND patients.
The difference in arm volume between SLNB and
ALND and the lack of difference between SLNB and
SLNB ? CLND agreed with the results of several other
studies, of which 2 studies based their results on arm vol-
ume and the other studies on changes in 1 or 2
circumferential measurements of the arm.
7,8,10,19,22,24
In contrast with our results, 2 studies described differ-
ences between SLNB and SLNB ? CLND. In one of these
studies, level III lymph node dissection had been per-
formed.
20 In the other study, lymphedema was measured
objectively and subjectively and the outcomes were com-
bined into 1 variable. Therefore, their ‘‘difference’’ score
also contained a subjective component.
11
TABLE 3 Signiﬁcant between subjects effects of treatment-related variables, GLM procedure
Variable Systemic therapy Radiotherapy Dissected lymph nodes
FP Effect size FP Effect size FP Effect size
Range of motion
D ant – ns – 3.5 .030
a .04 6.6 .002
c 0.08
D abd – ns – 4.6 .011
b .05 7.3 .001
d 0.08
D abdexo – ns – – ns – 4.4 .014
e 0.05
Arm volume
D vol 4.9 .028 .03 – ns – 4.8 .010
f 0.06
ns not signiﬁcant
a Bonferroni test: no versus breast ns, no versus breast and axilla P = .036, breast versus breast and axilla P = .031
b Bonferroni test: no versus breast ns, no versus breast and axilla P = .018, breast versus breast and axilla P = .008
c Bonferroni test:\3 versus 3–10 P = .003,\3 versus[10 P = .012, 3–10 versus[10 ns
d Bonferroni test:\3 versus 3–10 P = .004,\3 versus[10 P = .003, 3–10 versus[10 ns
e Bonferroni test:\3 versus 3–10 P = .042,\3 versus[10 P = .024, 3–10 versus[10 ns
f Bonferroni test:\3 versus 3–10 P = .068,\3 versus[10 P = .010, 3–10 versus[10 ns
2392 J. J. Kootstra et al.Our results also contrasted with those of 2 studies that
found no difference between SLNB and ALND.
4,16 One of
these studies recruited patients based on the intention to
treat principle, so the SLNB group included women in
whom SLNB was followed by CLND or radiotherapy to the
axilla.
4 In the other study, group comparisons were made
based on differences in the mean increase in arm volume
over 6 measurements.
16 Consequently, the course of the
changes in arm volume during follow-up was unclear.
Clinical Relevance
Although many of the results of our study were statis-
tically signiﬁcant, the clinical relevance of the time effects
and group effects appeared to be negligible for all the
variables. However, the standard deviations were wide,
which means that there were large differences between the
women within each of the groups, and that our population
deﬁnitely contained women with shoulder/arm functional
limitations. It is important to recognize these women at an
early stage and, if possible, to refer them for physiotherapy
or lymphapress treatment.
Other Treatment-Related Variables
The type of surgery and complications had no effect on
the longitudinal outcomes of shoulder function, arm func-
tion, or arm volume. An earlier study reported that women
who underwent mastectomy were more likely to report
limitations in their range of motion, while the evidence for
an effect of complications seems inconclusive.
34,35 Che-
motherapy signiﬁcantly affected arm volume, which to our
knowledge has not been previously reported in the litera-
ture. We found that patients who received radiotherapy to
the breast and the axilla experienced more range of motion
limitations than patients who had not undergone radio-
therapy or who had received radiotherapy to the breast only.
A previously published study comparing axillary radiation
with no axillary radiation in woman after modiﬁed radical
mastectomy and ALND reported comparable results on
range of motion.
36 Lastly, patients who had more than 3
lymph nodes removed reported having decreased range of
motion and increased arm volume compared with patients
from whom fewer than 3 nodes were removed. This last
ﬁnding is not surprising because fewer than 3 lymph nodes
were removed in all but 1 of the women in the SLNB group.
The results conﬁrm those found for groups according to
axillary surgery (SLNB, SLNB ? CLND, or ALND).
Study Limitations and Further Comments
Because of a number of limitations in our study, caution
is required in the interpretation of the results and their
generalization to the total population of breast cancer
patients. The number of participants was small in relation
to the number of statistical analyses. All women who
participated had stage I–II breast cancer, and only those
who were disease-free were included in the longitudinal
analyses.
The strengths of our study were the prospective design
and that the evaluations were done strictly according to
protocol using validated and standardized functional tests.
The difference score calculations between the affected and
nonaffected sides provided objective insight into the
shoulder/arm functional limitations that occurred on a
group level. However, the wide standard deviations indicate
large differences between individuals in each of the groups.
In conclusion, the limitations in shoulder function and
arm strength were most severe immediately after surgery
for breast cancer. At the 2-year follow-up, all women had
regained their preoperative level of arm muscle strength.
However, there were still limitations in their shoulder
function. It appeared that women in the SLNB group had
fewer limitations. Women in the ALND group showed
gradual lymphedema progression during the 2 years of
follow-up, whereas the women in the SLNB group did not
develop lymphedema. In the SLNB ? CLND group,
lymphedema occurred immediately after surgery, but did
not deteriorate over the 2-year period. The time effects and
group effects found in this study were of negligible clinical
relevance.
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